Joan Bargay Lleonart-rekin lankidetzan egindako argitalpenak (12)

2017

  1. Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma

    Blood

2016

  1. Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients

    Acta Haematologica, Vol. 136, Núm. 2, pp. 76-84

2014

  1. First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosaassociated lymphoid tissue lymphoma (MALT2008-01): A multicentre, single-arm, phase 2 trial

    The Lancet Haematology, Vol. 1, Núm. 3, pp. e104-e111

2013

  1. Predictive value of interim 18F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment

    Nuclear Medicine Communications, Vol. 34, Núm. 10, pp. 946-952

2005

  1. Long-term outcome of allogeneic PBSC transplantation in pediatric patients with hematological malignancies: A report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON) and the Spanish Group for Allogeneic Peripheral Blood Transplantation (GETH)

    Bone Marrow Transplantation, Vol. 36, Núm. 9, pp. 781-785

2004

  1. Risk assessment and outcome of chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell transplantation in pediatric patients

    Bone Marrow Transplantation, Vol. 34, Núm. 5, pp. 433-438

2003

  1. Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning

    Bone Marrow Transplantation, Vol. 31, Núm. 5, pp. 387-392

2002

  1. Myeloablative treatments for multiple myeloma: Update of a comparative study of different regimens used in patients from the Spanish Registry for transplantation in multiple myeloma

    Leukemia and Lymphoma, Vol. 43, Núm. 1, pp. 67-74

  2. Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34 + selected blood cells from HLA-identical siblings

    Blood, Vol. 100, Núm. 2, pp. 724-727

2001

  1. Allogeneic transplantation of CD34+ -selected cells from peripheral blood in patients with myeloid malignancies in early phase: A case control comparison with unmodified peripheral blood tranplantation

    Bone Marrow Transplantation, Vol. 28, Núm. 4, pp. 349-354

  2. Favourable effect of the combination of acute and chronic graft-versus-host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignancies

    British Journal of Haematology, Vol. 114, Núm. 3, pp. 544-550

1997

  1. Trasplante alogénico de progenitores hemopoyéticos de sangre periférica no manipulados: Experiencia española de 79 casos

    Sangre, Vol. 42, Núm. SUPPL. 1, pp. 42-43